These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36732477)

  • 1. Synapse-tuned CARs enhance immune cell anti-tumor activity.
    Chockley PJ; Ibanez-Vega J; Krenciute G; Talbot LJ; Gottschalk S
    Nat Biotechnol; 2023 Oct; 41(10):1434-1445. PubMed ID: 36732477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors.
    Zhang YT; Fu X; Ting Lim JJ; Zhang SX
    Cancer Lett; 2025 Jan; 608():217319. PubMed ID: 39489212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.
    Gaimari A; De Lucia A; Nicolini F; Mazzotti L; Maltoni R; Rughi G; Zurlo M; Marchesini M; Juan M; Parras D; Cerchione C; Martinelli G; Bravaccini S; Tettamanti S; Pasetto A; Pasini L; Magnoni C; Gazzola L; Borges de Souza P; Mazza M
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
    Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917
    [No Abstract]   [Full Text] [Related]  

  • 5. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function.
    Barden M; Elsenbroich PR; Haas V; Ertelt M; Pervan P; Velas L; Gergely B; Szöőr Á; Harrer DC; Bezler V; Holzinger A; Friis RUW; Vereb G; Schütz GJ; Schoeder CT; Hombach AA; Abken H
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39622582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 25th National and 11th International Annual Congress on Research and Technology of Iranian Medical Sciences Students, Urmia, Iran, 5-7 September, 2024.
    Moazed N; Tahmasebi Nezhad N; Karami Nezhad Z; Khosravi A
    Iran Biomed J; 2024 Dec; 28(7):40. PubMed ID: 39673405
    [No Abstract]   [Full Text] [Related]  

  • 7. Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.
    Torchiaro E; Cortese M; Petti C; Basirico' M; Invrea F; D'Andrea A; Franco L; Sangiolo D; Medico E
    J Transl Med; 2024 Dec; 22(1):1100. PubMed ID: 39627822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.
    Singh K; Rocco JM; Nussenblatt V
    Semin Hematol; 2024 Oct; 61(5):321-332. PubMed ID: 39379249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T cells secreting NGF-neutralizing scFv enhance efficacy in clear cell renal cell carcinoma by relieving immunosuppression through immunosympathectomy.
    Yang P; Chen X; Yu F; Wang L; Li M; Bai Z; Xu H
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39653553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virus and CAR-T cell therapy in solid tumors.
    Ponterio E; Haas TL; De Maria R
    Front Immunol; 2024; 15():1455163. PubMed ID: 39539554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of self-driving anti-αFR CAR-engineered NK cells based on IFN-γ and TNF-α synergistically induced high expression of CXCL10.
    He M; Ao X; Yang Y; Xu Y; Liu T; Ao L; Guo W; Xing W; Xu J; Qian C; Yu J; Xu X; Yi P
    Neoplasia; 2024 Dec; 58():101065. PubMed ID: 39366148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.
    Rotolo A; Atherton MJ
    Clin Cancer Res; 2024 Jun; 30(11):2359-2369. PubMed ID: 38573683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies.
    Lee S; Chae SJ; Jang IH; Oh SC; Kim SM; Lee SY; Kim JH; Ko J; Kim HJ; Song IC; Kim JK; Kim TD
    EBioMedicine; 2024 Dec; 110():105459. PubMed ID: 39579618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting metabolic pathway enhance CAR-T potency for solid tumor.
    Li W; Chen J; Guo Z
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113412. PubMed ID: 39454410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cells enhance EphA2 chimeric antigen receptor T cells cytotoxicity against glioblastoma via improving persistence.
    Zhang Y; Gu A; An Z; Huang S; Zhang C; Zhong X; Hu Y
    Hum Immunol; 2024 Nov; 85(6):111093. PubMed ID: 39243423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.
    Guo J; Wu Q; Li H; Liang C; Dai J; Zhang S; Dai C; Zhang J; Wen Y; Yang W
    Front Immunol; 2024; 15():1435934. PubMed ID: 39606226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-armored-cell therapy in solid tumor treatment.
    Liu Y; Xiao L; Yang M; Chen X; Liu H; Wang Q; Guo M; Luo J
    J Transl Med; 2024 Nov; 22(1):1076. PubMed ID: 39609705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants.
    Mei A; Letscher KP; Reddy S
    Curr Opin Biotechnol; 2024 Dec; 90():103223. PubMed ID: 39504625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing T-cell sources determines CAR-T cell activity in neuroblastoma.
    García-García L; G Sánchez E; Ivanova M; Pastora K; Alcántara-Sánchez C; García-Martínez J; Martín-Antonio B; Ramírez M; González-Murillo Á
    Front Immunol; 2024; 15():1375833. PubMed ID: 38601159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.